Particle Sciences has completed the clinical trial manufacture of vaginal rings under development for HIV prevention that are designed to deliver the pro-drug tenofovir disoproxil fumarate for 30 days. In studies conducted at the Center for Disease Control, the ring provided complete protection against the related virus, SHIV. The product is a drug-eluting device funded under an NIH grant led by Betsy Herold, M.D., Professor and Director, Translational Prevention Research Center at Albert Einstein College of Medicine.
 
Mark Mitchnick, M.D., Particle Sciences’ chief executive officer, commented, “Particle Sciences focuses on formulation design and manufacturing. Given the issues our clients face, the dosage forms we work with often require a high level of engineering and reducing complex formulations to commercially viable products is something we frequently do. The product itself was designed by Patrick Kiser, Ph.D., associate professor of Biomedical Engineering at Northwestern University. We have a long history with prevention technologies and were delighted to be able to work on this one.”